Related Experiment Video
Updated: Nov 10, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
CircSAMD4A contributes to cell doxorubicin resistance in osteosarcoma by regulating the miR-218-5p/KLF8 axis
Wei Wei1, Liefeng Ji1, Wanli Duan1
1Department of orthopedics, Shaoxing Shangyu People's Hospital, No. 517, Shimin Avenue, Baiguan Street, Shangyu District, Shaoxing, Zhejiang Province, 312300, China.
Abstract:
Circular RNA sterile alpha motif domain containing 4A (circSAMD4A) was found to be differentially expressed in osteosarcoma and contributed to the tumorigenesis of osteosarcoma. However, the role of circSAMD4A in doxorubicin (DXR) resistance of osteosarcoma is yet to be elucidated. Levels of circSAMD4A, microRNA (miR)-218-5p and Krüppel-like factor 8 (KLF8) were detected using quantitative reverse transcription-polymerase chain reaction. Western blot was applied to detect the protein levels of KLF8, cyclin D1 and p21. Cell viability, cell cycle, migration and invasion were analyzed using Cell Counting Kit-8 assay, flow cytometry and transwell assay, respectively. The interaction between miR-218-5p and circSAMD4A or KLF8 was verified using dual-luciferase reporter assay or RNA immunoprecipitation assay. In vivo experiments were performed using murine xenograft models. CircSAMD4A and KLF8 were elevated in osteosarcoma, and knockdown of circSAMD4A or KLF8 sensitized osteosarcoma cells to DXR by mediating resistant cell viability, migration and invasion inhibition, and cell cycle arrest in vitro. miR-218-5p was decreased in osteosarcoma, and miR-218-5p inhibition enhanced DXR resistance. Besides, miR-218-5p was found to bind to circSAMD4A or KLF8, and subsequent rescue experiments indicated that miR-218-5p inhibition reversed the inhibitory effects of circSAMD4A silencing on DXR resistance, and silencing miR-218-5p enhanced DXR resistance by targeting KLF8 in osteosarcoma cells. Moreover, circSAMD4A could indirectly regulate KLF8 via miR-218-5p. Additionally, circSAMD4A knockdown enhanced the cytotoxicity of DXR in osteosarcoma in vivo via regulating miR-218-5p and KLF8. In all, circSAMD4A enhanced cell DXR resistance in osteosarcoma by regulating the miR-218-5p/KLF8 axis, suggesting a novel therapeutic target for therapy-resistant osteosarcoma.
Insights
Circular RNA sterile alpha motif domain containing 4A (circSAMD4A) promotes doxorubicin resistance in osteosarcoma by regulating the miR-218-5p/KLF8 axis. Targeting circSAMD4A offers a potential strategy against therapy-resistant osteosarcoma.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Osteosarcoma is a primary bone malignancy with limited treatment options.
- Doxorubicin (DXR) resistance is a major challenge in osteosarcoma treatment.
- The role of circular RNAs, specifically circSAMD4A, in DXR resistance remains largely unknown.
Purpose of the Study:
- To investigate the role of circSAMD4A in doxorubicin resistance in osteosarcoma.
- To elucidate the underlying molecular mechanism involving miR-218-5p and KLF8.
- To evaluate circSAMD4A as a potential therapeutic target for DXR-resistant osteosarcoma.
Main Methods:
- Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blot for gene and protein expression analysis.
- Cell Counting Kit-8 assay, flow cytometry, and Transwell assays for functional studies (viability, cell cycle, migration, invasion).
- Dual-luciferase reporter and RNA immunoprecipitation assays to confirm molecular interactions; in vivo studies using murine xenograft models.
Main Results:
- CircSAMD4A and KLF8 were upregulated in osteosarcoma tissues and cells, while miR-218-5p was downregulated.
- Knockdown of circSAMD4A or KLF8 sensitized osteosarcoma cells to DXR, inhibiting viability, migration, invasion, and inducing cell cycle arrest.
- CircSAMD4A directly interacted with miR-218-5p and indirectly regulated KLF8 via miR-218-5p, exacerbating DXR resistance.
Conclusions:
- CircSAMD4A enhances doxorubicin resistance in osteosarcoma by modulating the miR-218-5p/KLF8 axis.
- CircSAMD4A represents a promising therapeutic target for overcoming DXR resistance in osteosarcoma.
- Targeting the circSAMD4A/miR-218-5p/KLF8 pathway could improve treatment efficacy for patients with resistant osteosarcoma.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Treatment Resistant Cancers
Abnormal Proliferation

